Healthcare ❯ Pharmaceuticals ❯ Drug Pricing

Medicaid

Prescription Drugs Pfizer Patient Access Direct-to-Consumer Sales Medicare Lower-Income Americans Most Favored Nation Pricing Cost Reduction Biosimilars and Generics Consumer Impact Access to Medicines Healthcare Sector Performance Health Equity Consumer Access Government Negotiations Federal Regulations

White House Projects $529 Billion in Savings From Trump’s MFN Drug Pricing Plan

Lawmakers question secret deals that rely on other countries paying more for drugs.

AbbVie Strikes Trump Drug-Pricing Deal, Pledges $100 Billion, Wins 3-Year Tariff Reprieve

Pfizer–Trump Drug-Pricing Deal and ‘TrumpRx’ Plan Jolt Health-Care Stocks Higher